David W. Osborne, Chief Technical Officer at Arcutis Biotherapeutics, Inc. (ARQT), sold 690 shares at $15.26 ($11K) on 2023-03-06, disclosed to the SEC on 2023-03-08.
Scheduled sale ($11k) by Chief Technical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ARQT | SELL | 2022-04-21 | $45K | — | Filing → |
| ARQT | SELL | 2022-03-07 | $14K | — | Filing → |
| ARQT | SELL | 2022-03-03 | $14K | — | Filing → |